ArticleAbdominal radiology (New York)2026
Prognostic factors and treatment response in previously treated hepatocellular carcinoma patients receiving Y-90 radioembolization combined with targeted-immunotherapy: an exploratory analysis.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From signal-intensity ratio to decision-grade triage in prostate MRI.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTo evaluate treatment response and identify factors associated with outcomes in previously treated hepatocellular carcinoma (HCC) patients receiving Y-90 radioembolization combined with targeted therapy and immunotherapy (Y-90 + TT + IT).
methodsThis retrospective study included 30 previously treated HCC patients (11 with prior surgery, 19 without) who received Y-90 + TT + IT. At a median follow-up of 9.7 months (95% CI, 8.5-13.9), 23 PFS events and 9 overall survival (OS) events occurred. Patient‑level response was assessed in 24 patients (all with PFS events or > 6‑month follow‑up without progression). Univariable Cox regression was used for PFS and OS; owing to few OS events (n = 9), OS analyses were exploratory. For PFS, an exploratory multivariable model (backward stepwise) was also constructed.
resultsObjective response rate was 37.5% (9/24) and disease control rate 75.0% (18/24); infiltrative imaging appearance was the only feature associated with non‑response (p = 0.042). Prior surgery was associated with worse PFS in both patient-level (HR 3.78, p = 0.004) and lesion-level (HR 3.32, p = 0.024) analyses; however, the lesion-level association was not confirmed in a sensitivity analysis restricted to one index lesion per patient (p = 0.128) and should be interpreted cautiously as it may reflect within‑patient clustering. Prior surgery remained significant in multivariable analysis (p = 0.004). In univariable analysis for OS, total bilirubin (p = 0.019), lesion number (p = 0.022), gamma-glutamyl transferase (GGT; p = 0.041), and tumor-to-normal liver uptake ratio (TNR; p = 0.008) were associated with OS.
conclusionsIn this exploratory cohort of previously treated HCC patients receiving Y-90 + TT + IT, prior surgery was associated with worse patient‑level PFS. Infiltrative imaging appearance was associated with non‑response. In univariable analysis, GGT, TNR, total bilirubin, and lesion number showed exploratory associations with OS. These findings generate hypotheses and require validation in larger prospective studies.
Indexed as
Identifiers
42517902What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.